Lysosomal storage diseases

FM Platt, A d'Azzo, BL Davidson, EF Neufeld… - Nature reviews Disease …, 2018 - nature.com
Lysosomal storage diseases (LSDs) are a group of over 70 diseases that are characterized
by lysosomal dysfunction, most of which are inherited as autosomal recessive traits. These …

Advances in therapies for neurological lysosomal storage disorders

S Ellison, H Parker, B Bigger - Journal of Inherited Metabolic …, 2023 - Wiley Online Library
Abstract Lysosomal Storage Disorders (LSDs) are a diverse group of inherited, monogenic
diseases caused by functional defects in specific lysosomal proteins. The lysosome is a …

Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches

N Benetó, L Vilageliu, D Grinberg, I Canals - International Journal of …, 2020 - mdpi.com
Sanfilippo syndrome or mucopolysaccharidosis III is a lysosomal storage disorder caused by
mutations in genes responsible for the degradation of heparan sulfate, a glycosaminoglycan …

[HTML][HTML] Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal

S Marcó, V Haurigot, ML Jaén, A Ribera… - … Therapy Methods & …, 2021 - cell.com
Delivery of adeno-associated viral vectors (AAVs) to cerebrospinal fluid (CSF) has emerged
as a promising approach to achieve widespread transduction of the central nervous system …

How close are we to therapies for Sanfilippo disease?

L Gaffke, K Pierzynowska, E Piotrowska… - Metabolic brain …, 2018 - Springer
Sanfilippo disease is one of mucopolysaccharidoses (MPS), a group of lysosomal storage
diseases characterized by accumulation of partially degraded glycosaminoglycans (GAGs) …

Cerebral organoids: a human model for AAV capsid selection and therapeutic transgene efficacy in the brain

JA Depla, M Sogorb-Gonzalez, LA Mulder… - … Therapy Methods & …, 2020 - cell.com
The development of gene therapies for central nervous system disorders is challenging
because it is difficult to translate preclinical data from current in vitro and in vivo models to …

[HTML][HTML] A cure for Sanfilippo syndrome? A summary of current therapeutic approaches and their promise

Y Pearse, M Iacovino - Medical research archives, 2020 - ncbi.nlm.nih.gov
Abstract Mucopolysaccharidoses III (MPS III, Sanfilippo syndrome) is a subtype of the
Mucopolysaccharidoses (MPS), a group of inherited lysosomal disorders caused by a …

Compositions for the treatment of disease

S Paul, DT Ward - US Patent 11,326,182, 2022 - Google Patents
The invention provides compositions and methods for the preparation, manufacture and
therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral …

Chimeric capsids

R Kotin, J Hou, J McLaughlin - US Patent 10,577,627, 2020 - Google Patents
Parvoviridae family viruses are small non-enveloped icosahedral capsid viruses
characterized by a single stranded DNA genome. Parvoviridae family viruses consist of two …

Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector

CJ Rouse, K Hawkins, N Kabbej… - Human Molecular …, 2023 - academic.oup.com
Abstract Mucopolysaccharidosis type IIIB (MPS IIIB) is an autosomal recessive lysosomal
storage disease caused by mutations in the gene that encodes the protein N-acetyl …